Determination Concentrations of Tissue Factor Pathway Inhibitor and their Changes during Estrogen Replacement Therapy
T. Fait 1; B. Trnková 3; M. Koštířová 3; M. Vráblík 2
Gynekologicko-porodnická klinika VFN Praha a 1. LF UK, Praha, přednosta prof. MUDr. A. Martan, DrSc.
1; III. interní klinika VFN Praha a 1. LF UK, Praha, přednosta prof. MUDr. Š. Svačina, DrSc.
2; Ústav klinické biochemie VFN Praha a l. LF UK, Praha, přednosta prof. MUDr. T. Zima, DrSc.
Čes. Gynek.2007, 72, č. 5 s. 343-347
The purpose of the present study was to determine changes of tissue factor pathway inhibitor (TFPI) as a biochemical risk factors of thromboembolism during the use of different administration methods of the early estrogen replacement therapy.
Prospective randomized cross-over trial.
General Faculty Hospital Prague.
In a 12-week prospective, randomized, interventional, cross-over trial, estradiol was administered orally in a dose of 2 mg daily or transdermally in a dose of 0,05 mg daily. Forty-five healthy postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49 ± 6 years. An enzymatic method (IMUBIND Total TFPI ELISA test) was employed for the determination of TFPI.
After the oral therapy, the average value of TFPI decreased statistically significantly (p <0.0001) from 87.5 ± 39.1 ng/ml to 68 ± 37.49 ng/ml. Conclusion: Statistically the oral therapy reduced significantly TFPI compared with the transdermal method of administration. In spite of the fact that these changes cannot be unambiguously considered as risky and that the zero change of D-dimers suggests that there was no activation of the coagulation cascade, we consider the neutral effect of the transdermal therapy as more beneficial. The lack of manifestations of the coagulation cascade activation demonstrates the safety of both administration forms of the estrogen replacement therapy in the case of the early administration.
estrogen replacement therapy, thromboembolism, TFPI
Gynaecology and obstetrics